The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis.

Abstract Introduction The persistent challenge of temozolomide (TMZ) resistance and the eventual recurrence of tumors underscore the need for ongoing research and the development of novel therapeutic strategies. We aim to consolidate existing evidence related to the safety and efficacy of TMZ as adj...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	BMC Cancer
المؤلفون الرئيسيون:	Made Agus Mahendra Inggas, Utsav Patel, Jeremiah Hilkiah Wijaya, Nina Otinashvili, Vyshnav Rajagopal Menon, Abhay Krishnan Iyer, Tawfiq Turjman, Surbhi Dadwal, Mari Gadaevi, Azada Ismayilova, Shiva Jashwanth Gaddam, Prakriti Arya, Nihar Upadhyay, Saurabh Kataria
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	BMC 2025-03-01
الموضوعات:	Glioblastoma Overall survival Progression free survival Temozolomide.
الوصول للمادة أونلاين:	https://doi.org/10.1186/s12885-025-13757-1

مواد مشابهة

Comparison of multi-cycle and standard-cycle temozolomide chemotherapies in patients with glioblastoma undergoing surgery and successive radiotherapy
حسب: Yuan Fu, وآخرون
منشور في: (2023-06-01)

Resveratrol and temozolomide induce apoptosis and suppress proliferation in glioblastoma cells via the apoptotic signaling pathway
حسب: Görkem Tutal Gürsoy, وآخرون
منشور في: (2025-08-01)

The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review
حسب: Ehsan Alimohammadi, وآخرون
منشور في: (2020-02-01)

Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme—A Literature Review and Clinical Outcomes
حسب: Marcin Jezierzański, وآخرون
منشور في: (2024-07-01)

Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study)
حسب: Wan-Soo Yoon, وآخرون
منشور في: (2023-06-01)

Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma
حسب: Lei She, وآخرون
منشور في: (2021-07-01)

Temozolomide in treatment resistant prolactinomas
حسب: V. N. Shree, وآخرون
منشور في: (2018-08-01)

Comparative proteogenomic characterization of glioblastoma
حسب: Samia Asif, وآخرون
منشور في: (2019-06-01)

MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value
حسب: Henning Leske, وآخرون
منشور في: (2023-08-01)

Methylation associated with long- or short-term survival in glioblastoma patients from the Nordic phase 3 trial
حسب: Małgorzata Łysiak, وآخرون
منشور في: (2022-08-01)

The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation
حسب: Francesco Marchi, وآخرون
منشور في: (2020-01-01)

The Impact of <i>MGMT</i> Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma
حسب: Nikola Jovanović, وآخرون
منشور في: (2019-02-01)

Quinacrine enhances temozolomide cytotoxicity in temozolomide-sensitive and -resistant glioblastoma cells
حسب: Pingde Zhang, وآخرون
منشور في: (2018-01-01)

Importance of Autophagy Regulation in Glioblastoma with Temozolomide Resistance
حسب: Young Keun Hwang, وآخرون
منشور في: (2024-08-01)

Temozolomide for aggressive pituitary tumors:-A literature review
حسب: Hu Hui-zheng, وآخرون
منشور في: (2024-02-01)

Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil
حسب: Karoline Almeida Lima, وآخرون
منشور في: (2023-04-01)

Dose and Efficacy of Bevacizumab in Recurrent High-Grade Gliomas: A Retrospective Study
حسب: Bai X, وآخرون
منشور في: (2024-11-01)

Extended dosing (12 cycles) vs conventional dosing (6 cycles) of adjuvant temozolomide in adults with newly diagnosed high-grade gliomas: a randomized, single-blind, two-arm, parallel-group controlled trial
حسب: Kazem Anvari, وآخرون
منشور في: (2024-05-01)

Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors
حسب: Supriya Mallick, وآخرون
منشور في: (2015-01-01)

Response to Temozolomide in patients with metastatic melanoma in a third level medical facility
حسب: Selene Mejía-Cabrera, وآخرون
منشور في: (2022-03-01)

A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules
حسب: François Ducray, وآخرون
منشور في: (2023-11-01)

Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights
حسب: Hengzeng Li, وآخرون
منشور في: (2025-06-01)

Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
حسب: Yu-Ling Tsai, وآخرون
منشور في: (2020-09-01)

Temozolomide Chronotherapy in Glioma: A Systematic Review
حسب: Jason L. Jia, وآخرون
منشور في: (2023-02-01)

S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial
حسب: Yihebali Chi, وآخرون
منشور في: (2022-12-01)

Long term survival in a patient with recurrent metastatic Ewing sarcoma treated with irinotecan and temozolomide
حسب: Hakan Gelincik, وآخرون
منشور في: (2016-12-01)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
حسب: Jia Zhu, وآخرون
منشور في: (2022-03-01)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
حسب: Monique eDontenwill, وآخرون
منشور في: (2012-10-01)

Targeting of temozolomide using magnetic nanobeads: an in vitro study
حسب: Berna Gürten, وآخرون
منشور في: (2020-09-01)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
حسب: Makoto Ohno, وآخرون
منشور في: (2019-11-01)

Down-Regulation of CEND1 Expression Contributes to The Progression and Temozolomide Resistance of Glioma
حسب: Houjun Zhou, وآخرون
منشور في: (2023-04-01)

TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma
حسب: Jian Yu, وآخرون
منشور في: (2022-07-01)

Temozolomide-associated blepharoconjunctivitis: a case report
حسب: Tom Kornhauser, وآخرون
منشور في: (2024-04-01)

Meningeal seeding from glioblastoma multiforme treated with radiotherapy and temozolomide
حسب: Lu-Ting Kuo, وآخرون
منشور في: (2017-01-01)

Is Autophagy Inhibition in Combination with Temozolomide a Therapeutically Viable Strategy?
حسب: Ahmed M. Elshazly, وآخرون
منشور في: (2023-02-01)

Should CD4 Levels be Monitored in a Patient on Temozolomide?
حسب: Sriram Gonakoti, وآخرون
منشور في: (2021-03-01)

99mTc-Tetrofosmin uptake correlates with the sensitivity of glioblastoma cell lines to temozolomide
حسب: George Alexiou, وآخرون
منشور في: (2017-01-01)

Pediatric Non–Brain Stem High-Grade Glioma: A Single-Center Experience
حسب: Ehsan Alimohammadi, وآخرون
منشور في: (2020-06-01)

Prognostic factors for glioblastoma: a retrospective single-center analysis of 176 adults
حسب: HUANG Guohao, وآخرون
منشور في: (2024-09-01)

Expression of STAT3 and hypoxia markers in long-term surviving malignant glioma patients
حسب: Katerina Dvorakova, وآخرون
منشور في: (2024-04-01)